Asensus Surgical, Inc. (NYSE American: ASXC ) reported its Q2 2024 financial results and announced a definitive merger agreement with KARL STORZ. Key points include: 1. KARL STORZ will acquire Asensus for $0.35 per share in cash. 2. Q2 2024 revenue: $2.2 million, up from $1.1 million in Q2 2023. 3. Cash and equivalents: $7.8 million as of June 30, 2024. 4. Net loss: $25.7 million ($0.09 per share) vs $20.7 million in Q2 2023. 5. Adjusted net loss: $18.1 million ($0.07 per share). The company urges stockholders to vote on the merger by August 20, 2024. If not approved, Asensus may seek bankruptcy protection.